NRx Pharmaceuticals to effect 1-for-10 reverse stock split effective April 1, 2024 to maintain Nasdaq listing

NRX Pharmaceuticals, Inc.

Reverse stock split at 1:10 ratio; shares outstanding reduced from ~95.7M to ~9.57M.
Effective at 4:30 p.m. ET on April 1, 2024; trading on split-adjusted basis begins April 2, 2024 under symbol NRXP.
Fractional shares rounded up to nearest whole share; par value unchanged.
Chairman cites upcoming clinical trial readouts, planned NDA filing, and dividend of HOPE Therapeutics shares.
CUSIP changes to 629444209; stockholders need not exchange certificates.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

NRX Pharmaceuticals, Inc.: Amendment to certificate of incorporation to effect a 1-for-10 reverse stock split of common stock, effective April 1, 2024 (effective 2024-04-01).

Change: charter amendment
Effective: 2024-04-01

Exact text from the filing

On March 28, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) announced that it had filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “ Charter Amendment ”) to effect a 1-for-10 reverse stock split (the “ Reverse Stock Split ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), effective as of 4:30 p.m. Eastern Standard Time on April 1, 2024 (the “ Effective Time ”).

View on SEC.gov

261 governance changes filed in the last 30 days. Browse all governance changes →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-040608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.